Talimogene laherparepvec for treating unresectable metastatic melanoma (TA410)
Evidence-based recommendations on talimogene laherparepvec (Imlygic) for treating unresectable metastatic melanoma in adults
Search results
1178 results
-
-
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion (TA409)
Evidence-based recommendations on aflibercept (Eylea) for treating visual impairment caused by macular oedema after branch retinal vein occlusion
-
Pegaspargase for treating acute lymphoblastic leukaemia (TA408)
Evidence-based recommendations on pegaspargase (Oncaspar) for treating acute lymphoblastic leukaemia
-
Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors (TA407)
Evidence-based recommendations on secukinumab (Cosentyx) for ankylosing spondylitis (spondyloartritis) that has not responded well enough to conventional
-
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (TA406)
Evidence-based recommendations on crizotinib (Xalkori) for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (NSCLC) in adults
-
Trifluridine–tipiracil for previously treated metastatic colorectal cancer (TA405)
Evidence-based recommendations on trifluridine–tipiracil (Lonsurf) for previously treated metastatic colorectal cancer in adults
-
Ceritinib for untreated ALK-positive non-small-cell lung cancer (TA500)
Evidence-based recommendations on ceritinib (Zykadia) for untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer (NSCLC)
-
Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)
Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults
-
Lenvatinib with everolimus for previously treated advanced renal cell carcinoma (TA498)
Evidence-based recommendations on lenvatinib (Kisplyx) with everolimus for previously treated advanced renal cell carcinoma (kidney cancer) in adults
-
Golimumab for treating non-radiographic axial spondyloarthritis (TA497)
Evidence-based recommendations on golimumab (Simponi) for severe non-radiographic axial spondyloarthritis in adults
-
Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA496)
Evidence-based recommendations on ribociclib (Kisqali) as initial endocrine-based therapy for hormone-receptor positive, human epidermal growth factor receptor
-
Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)
Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone receptor-positive, HER2-negative, locally advanced or
-
Naltrexone–bupropion for managing overweight and obesity (TA494)
Evidence-based recommendations on naltrexone–bupropion (Mysimba) for managing overweight and obesity in adults
-
Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)
Evidence-based recommendations on ibrutinib (Imbruvica) for treating Waldenstrom's macroglobulinaemia (non-Hodgkin lymphoma) in adults after at least 1 therapy
-
Vismodegib for treating basal cell carcinoma (TA489)
Evidence-based recommendations on vismodegib (Erivedge) for treating basal cell carcinoma (BCC; non-melanoma skin cancer; rodent ulcers) in adults
-
Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours (TA488)
Evidence-based recommendations on on regorafenib (Stivarga) for previously treated gastrointestinal stromal tumours in adults
-
Venetoclax for treating chronic lymphocytic leukaemia (TA487)
Evidence-based recommendations on venetoclax (Venclyxto) for treating chronic lymphocytic leukaemia in adults
-
Aflibercept for treating choroidal neovascularisation (TA486)
Evidence-based recommendations on aflibercept (Eylea) for treating myopic choroidal neovascularisation in adults
-
Sarilumab for moderate to severe rheumatoid arthritis (TA485)
Evidence-based recommendations on sarilumab (Kevzara) for treating moderate to severe rheumatoid arthritis in adults
-
Methylnaltrexone bromide for treating opioid-induced constipation (terminated appraisal) (TA468)
NICE was unable to make a recommendation about the use in the NHS of methylnaltrexone bromide for treating opioid-induced constipation because no evidence was
-
Baricitinib for moderate to severe rheumatoid arthritis (TA466)
Evidence-based recommendations on baricitinib (Olumiant) for moderate to severe rheumatoid arthritis in adults
-
Cabozantinib for previously treated advanced renal cell carcinoma (TA463)
Evidence-based recommendations on cabozantinib (Cabometyx) for previously treated advance renal cell carcinoma (kidney cancer) in adults
-
Roflumilast for treating chronic obstructive pulmonary disease (TA461)
Evidence-based recommendations on roflumilast (Daxas) for treating chronic obstructive pulmonary disease (COPD) in adults with chronic bronchitis
-
Adalimumab and dexamethasone for treating non-infectious uveitis (TA460)
Evidence-based recommendations on adalimumab (Humira) and dexamethasone (Ozurdex) for treating non-infectious uveitis in adults
-
Ustekinumab for moderately to severely active Crohn's disease after previous treatment (TA456)
Evidence-based recommendations on ustekinumab (Stelara) for previously treated moderately to severely active Crohn’s disease in adults
-
Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for treating plaque psoriasis in children and young people
-
Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal) (TA454)
NICE was unable to make a recommendation about the use in the NHS of daratumumab with lenalidomide and dexamethasone for multiple myeloma because no evidence
-
Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) (TA453)
NICE is unable to make a recommendation about the use in the NHS of bortezomib for treating multiple myeloma after second or subsequent relapse because no
-
Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) (TA452)
NICE is unable to make a recommendation about the use in the NHS of ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53
-
Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia (TA451)
Evidence-based recommendations on ponatinib (Iclusig) for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia in adults
-
Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA221)
Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune (idiopathic) thrombocytopenic purpura (ITP)
-
Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease (TA223)
Evidence-based recommendations on cilostazol (Pletal), naftidrofuryl oxalate (Praxilene), pentoxifylline (Trental 400) and inositol nicotinate (Hexopal)
-
Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs (TA225)
Evidence-based recommendations on golimumab (Simponi) for treating rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs
-
Dexamethasone intravitreal implant for the treatment of macular oedema secondary to retinal vein occlusion (TA229)
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating macular oedema secondary to retinal vein occlusion
-
Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer) (TA23)
Evidence-based recommendations on temozolomide (Temodal) for malignant glioma in children over 3 years, young people and adults.
-
Bivalirudin for the treatment of ST-segment-elevation myocardial infarction (TA230)
Evidence-based recommendations on bivalirudin (Angiox) for treating ST-segment-elevation myocardial infarction (STEMI)
-
Agomelatine for the treatment of major depressive episodes (terminated appraisal) (TA231)
NICE is unable to make a recommendation about the use in the NHS of agomelatine for major depressive episodes because no evidence submission was received
-
Bosutinib for untreated chronic myeloid leukaemia (terminated appraisal) (TA576)
NICE is unable to make a recommendation about the use in the NHS of bosutinib for untreated chronic myeloid leukaemia because no evidence submission was
-
Cabozantinib for previously treated advanced hepatocellular carcinoma (terminated appraisal) (TA582)
NICE is unable to make a recommendation about the use in the NHS of cabozantinib (Cometriq) for previously treated advanced hepatocellular carcinoma in adults
-
Dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive non-small-cell lung cancer (terminated appraisal) (TA564)
NICE is unable to make a recommendation about the use in the NHS of dabrafenib with trametinib for treating advanced metastatic BRAF V600E mutation-positive
-
Guidance on the use of electroconvulsive therapy (TA59)
Evidence-based recommendations on electroconvulsive therapy (ECT) for treating severe depressive illness, mania and catatonia
-
Decitabine for untreated acute myeloid leukaemia (terminated appraisal) (TA548)
NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was
-
Denosumab for preventing skeletal-related events in multiple myeloma (terminated appraisal) (TA549)
NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence
-
Guidance on the use of paclitaxel in the treatment of ovarian cancer (TA55)
Evidence-based recommendations on paclitaxel (Taxol) for treating ovarian cancer
-
Abatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) (TA568)
NICE is unable to make a recommendation on abatacept (Orencia) for treating psoriatic arthritis after DMARDs in adults because of no evidence submission from
-
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal) (TA570)
NICE is unable to make a recommendation about the use in the NHS of pembrolizumab (Keytruda) for treating recurrent or metastatic squamous cell carcinoma of the
-
Padeliporfin for untreated localised prostate cancer (TA546)
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults
-
Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours (TA539)
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults
-
Lenalidomide with rituximab for previously treated follicular lymphoma (TA627)
Evidence-based recommendations on lenalidomide (Revlimid) with rituximab for previously treated follicular lymphoma (grade 1 to 3A) in adults
-
Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer (TA628)
Evidence-based recommendations on lorlatinib (Lorviqua) for previously treated ALK-positive advanced non-small-cell lung cancer in adults